HFA
ITRM

Hoover Financial Advisors’s Iterum Therapeutics ITRM Stock Holding History

Hoover Financial Advisors’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$1K Hold
33
– – ﹤0.01% 612
2021
Q1 		$1K Buy
+33
New +$786 ﹤0.01% 564

Other funds holding ITRM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
KFS
Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Hoover Financial Advisors's ITRM Position: Q2 2021 in Review

Hoover Financial Advisors held its Iterum Therapeutics (ITRM) position steady in Q2 2021 at 33 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #612.

Hoover Financial Advisors first reported a position in ITRM in Q1 2021 and has held it in 2 quarters since. 44 funds tracked by Wall St. Rank hold ITRM as of Q2 2021.

  • Hoover Financial Advisors held 33 shares of Iterum Therapeutics worth $1K as of Q2 2021.
  • Hoover Financial Advisors left its Iterum Therapeutics share count unchanged in Q2 2021.
  • Iterum Therapeutics made up ﹤0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #612 holding.
  • Hoover Financial Advisors first reported a position in Iterum Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • 44 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.